Smith, J. A., Kitt, M. M., Morice, A., Birring, S. S., McGarvey, L. P., Sher, M. R., Li, Y. P., Wu, W. C., Xu, Z. J., Muccino, D. R., Ford, A. P., Hull, J., Carr, W. W., Goldsobel, A. B., Gross, G. N., Holcomb, J. R., Hussain, I., Spangenthal, S., Storms, W., Elkayam, D., …Iyer, V. (2020). Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial. The lancet. Respiratory medicine, 8(8), 775-785. https://doi.org/10.1016/S2213-2600%2819%2930471-0